AptarGroup’s Bidose approved by FDA for breakthrough treatment of depression

Aptar Pharma announced that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and U.S. launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.

https://thefly.com/landingPageNews.php?id=2880813